Abstract
This article presents the analytical perspective of The HPV Vaccines Biological Impossibilities (HVBI) Theory by Praveen Dalal, which argues that post‑2006 narratives surrounding HPV vaccination have overshadowed the long‑established roles of natural immunity, screening, and treatment in reducing cervical cancer incidence and mortality. According to this theory, major declines in HPV‑related cancers occurred between 1970 and 2006—well before the introduction of HPV vaccines—due to improved hygiene, lifestyle changes, and widespread screening programs. The HVBI Theory contends that after 2006, screening and treatment appear to have “disappeared” from public‑health narratives, with vaccines being credited for outcomes historically driven by other factors. Using natural‑history timelines, hypothetical progression models, and comparative international data, the article examines the biological implausibility of short‑term vaccine‑impact claims and argues that vaccinated cohorts will not reach cancer‑risk age until 2028–2040. The analysis highlights the need for long‑term, biologically consistent evaluation of HPV vaccine efficacy.
Hijacking Of Medical Science By HPV Vaccines Lobby
The HVBI Theory begins with a simple but powerful question: If screening and treatment were effective before 2006, why do they seem to have vanished from the narrative after HPV vaccines were introduced? For decades, cervical cancer incidence and mortality declined steadily across countries due to natural immunity, lifestyle improvements, Pap smear programs, and accessible treatment. Yet, after 2006, many public‑health claims attribute these declines almost exclusively to HPV vaccines. The HVBI Theory argues that this shift is not supported by biological timelines or historical data.
A central premise of the theory is that over 95% of HPV infections clear naturally, including high‑risk types such as HPV‑16 and HPV‑18. Only about 5% persist, typically in individuals with weak or compromised immune systems. Even among these, many infections regress at CIN1, CIN2, or even CIN3 stages. Historically, screening programs detected high‑grade lesions early, and treatment prevented progression to invasive cancer. According to the HVBI Theory, when countries now claim that HPV vaccines “saved lives,” they are often attributing to vaccines what natural immunity and screening had already been achieving for decades.
Sweden provides a striking example. The country claims that HPV vaccination saved 200 lives between 2006 and 2026, averaging 10 lives per year. The HVBI Theory argues that these lives were saved by multiple factors—natural immunity, screening, treatment, improved healthcare—and that attributing them to vaccines in any manner is scientifically unsound. The theory further argues that vaccinated cohorts from 2007–2010 will not reach cancer‑risk age until 2027–2040, making current claims of vaccine‑driven cancer reduction biologically impossible.
Besides Sweden, the HVBI Theory has also debunked pharma‑funded studies from the UK, Australia, and India, showing that declines in cervical cancer are natural and healthcare‑driven, not vaccine‑driven. More debunked bogus studies are in pipeline.
To illustrate natural progression, the HVBI Theory uses a stepwise model for 100,000 hypothetical HPV infections. According to this model, 95,000 clear naturally within two years, while 5,000 persist. Of these, 3,000 develop CIN1 and 2,000 develop CIN2/3 over 10–15 years. Only about 400 progress to invasive cancer over decades, and roughly 180 eventually result in death. The theory argues that when vaccines claim to prevent deaths, they are often credited with preventing outcomes that would have been prevented by natural immunity or screening.
HVBI Theory Tables Analyses And The Biological Impossibilities
Table 1: HPV‑16 And HPV‑18 Natural History, Progression, And Clinical Timelines (Base Year: 2010)
| Immune Category | Clearance / Persistence | CIN 2/3 Appearance | Invasive Cancer Timeline | Notes |
|---|---|---|---|---|
| Normal Immune System | >90% clear within 1–2 years | None | None | Infection transient (HPV‑16/18) |
| Weak Immune System | Persistence 10–15 years | CIN3 ~2030 | Cancer ~2040 | Long natural timeline |
| Very Weak Immune System | Rapid persistence | CIN3 ~2020 | Cancer ~2030 | Accelerated but ≥10 years |
| Immunocompromised | Accelerated persistence | CIN3 ~2015 | Cancer ~2020 | Only group with CIN3 within 5 years |
Analysis:
This table forms the biological foundation of the HVBI Theory. It shows that CIN3 cannot appear within 3–7 years for individuals with normal, weak, or even very weak immune systems. Only immunocompromised individuals progress within five years, yet their immune dysfunction raises questions about vaccine efficacy. The HVBI Theory argues that vaccine trials claiming early CIN3 prevention contradict these natural timelines, as CIN3 simply cannot exist yet in the majority of vaccinated cohorts.
Table 2: CIN3 Progression Timelines For HPV‑16 And HPV‑18 (Base Year: 2010)
| Immune Category | Time: Infection → CIN3 | Time: CIN3 → AIS | Notes |
|---|---|---|---|
| Weak Immune System | ~20 years → 2030 | ~5 years → 2035 | CIN3 appears only after 20 years |
| Very Weak Immune System | ~10 years → 2020 | ~5 years → 2025 | CIN3 appears after 10 years |
| Immunocompromised | ~5 years → 2015 | ~2 years → 2017 | CIN3 appears rapidly |
Analysis:
Table 2 reinforces the HVBI Theory’s argument that CIN3 requires long biological timelines—10 to 20 years for most individuals. Therefore, vaccine trials conducted over 3–7 years cannot logically detect CIN3 prevention. The theory argues that such claims are based on lesions that have not yet appeared and are thus biologically impossible.
Table 3: Ideal CIN3 Testing Timeline (For Girl Aged 13 In 2010 And 20 In 2017, HPV‑16 And HPV‑18)
| Immune Category | Natural CIN3 Onset | Biologically Impossible Before | Ideal Testing Window | Rationale |
|---|---|---|---|---|
| Normal Immune System | No CIN3 | CIN3 progression impossible | Not applicable | >90% clearance; transient infection |
| Weak Immune System | ~2030 (age 33) | Before ~2025 (age 28) | 2028–2030 | CIN3 appears only after ~20 years |
| Very Weak Immune System | ~2020 (age 23) | Before ~2018 (age 21) | 2018–2020 | CIN3 onset ~10 years post‑infection |
| Immunocompromised | ~2015 (age 18) | Before ~2014 (age 17) | 2014–2015 | CIN3 onset ~5 years post‑infection |
Analysis:
This case study demonstrates that CIN3 cannot appear in vaccinated cohorts until decades after vaccination. For a girl vaccinated in 2010, CIN3 would not naturally appear until 2020–2030 depending on immune status. The HVBI Theory argues that vaccine claims of preventing CIN2/3 within a few years are inconsistent with these biological realities.
Table 4: Claimed Deaths Saved By HPV Vaccination (2006–2026)
| Rank | Country | 2006 Deaths (k) | 2006 DPR | 2026 Deaths (k) | 2026 DPR | ASR 2006 | ASR 2026 | Vaccination Start | Claimed Deaths Saved |
|---|---|---|---|---|---|---|---|---|---|
| 1 | United States | 5.0 | 0.0017 | 3.5 | 0.0012 | ~6 | ~4 | 2006 | 1,500 |
| 2 | United Kingdom | 2.5 | 0.0042 | 1.5 | 0.0025 | ~7 | ~5 | 2008 | 1,000 |
| 3 | Sweden | 0.5 | 0.0056 | 0.3 | 0.0032 | ~8 | ~5 | 2007 | 200 |
| 4 | Australia | 0.8 | 0.0040 | 0.5 | 0.0025 | ~8 | ~5 | 2007 | 300 |
| 5 | India | 47.0 | 0.0040 | 42.0 | 0.0028 | 14 | 10 | 2026 | 5,000 |
| 6 | Global Avg | 180.0 | 0.0028 | 140.0 | 0.0019 | 14 | 9 | — | 40,000 |
Analysis:
The HVBI Theory argues that these claimed “lives saved” overlap with long‑term declines already driven by natural immunity, screening, and healthcare improvements. Since vaccinated cohorts have not yet reached cancer‑risk age, the theory contends that attributing these declines to vaccines is premature.
Comparative Country Analysis
Comparative Table: Pre‑ And Post‑Vaccine Declines With HVBI Theory Interpretation
| Country | Pre‑Vaccine Decline (1970–2006) | Post‑Vaccine Decline (2006–2026) | HVBI Theory Interpretation |
|---|---|---|---|
| UK | Incidence ↓65%, Mortality ↓64% | Incidence ↓29% | Declines due to screening; vaccinated cohorts not yet at cancer‑risk age. |
| Australia | Incidence ↓58–60%, Mortality ↓60% | Incidence ↓37.5%, Mortality ↓25% | Natural immunity + Pap smears drove declines; vaccine attribution premature. |
| Sweden | Incidence ↓65%, Mortality ↓67% | Incidence ↓33%, Mortality ↓40% | Claims ignore 15–20 year latency; vaccinated cohorts reach risk age ~2027–2037. |
| India | Mortality ↓ steadily since 1970 | Vaccination began 2026 | Declines natural; vaccinated cohorts reach risk age ~2046–2056. |
Analysis:
Across all countries examined, the HVBI Theory identifies a consistent pattern: the steepest declines occurred before vaccines existed. Post‑2006 declines are smaller and fall within natural or screening‑driven expectations. The theory argues that attributing these declines to vaccines contradicts both historical data and biological timelines.
Conclusion
The HVBI Theory asserts that the disappearance of screening and treatment from post‑2006 narratives has created a distorted picture of HPV‑related cancer prevention. According to this perspective, natural immunity clears most infections, screening detects high‑grade lesions early, and treatment prevents progression—yet these contributions are now overshadowed by vaccine‑centric claims.
The theory argues that biological timelines make short‑term vaccine‑impact claims implausible, as vaccinated cohorts will not reach cancer‑risk age until 2028–2040. Comparative international data further suggest that major declines occurred long before vaccines were introduced.
The HVBI Theory therefore calls for long‑term, biologically consistent evaluation of HPV vaccine efficacy and its serious adverse effects and cautions against attributing decades‑long declines to interventions too recent to have produced them. In fact, HPV vaccines have slowed down the decline trend that was there before vaccines were rolled out.